News
Media
Podcasts
Conferences
Journals
Events
CME
Partners
Subscribe
Resources

Viewing

Opinion|Videos|February 14, 2025

Perspectives on the Usefulness of Real-world Data

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Episodes in this series

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 2 Advantages of the molecular structure of aflibercept

EP. 2 Advantages of the molecular structure of aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 10 Safety Profile of New Therapies

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

How do real-world data contribute to understanding the effectiveness of a therapy? What challenges arise when translating clinical trial results into real-world practice?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Content

(Modern Retina) Could FLIO predict how fast geographic atrophy will grow?

Could FLIO predict how fast geographic atrophy will grow?

ByModern Retina Staff

July 4th 2026

(Modern Retina) Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

ByModern Retina Staff

July 3rd 2026

(Image credit: Modern Retina) Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

ByModern Retina Staff

June 30th 2026

Arshad M. Khanani, MD | Modern Retina

Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year

ByArshad M. Khanani, MD, MA, FASRS

June 29th 2026

Viridian Therapeutics' Lumvoa receives FDA approval for thyroid eye disease across active and chronic stages

ByModern Retina Staff

June 27th 2026

Latest CME

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Eye Care Network - Ophthalmology Times

FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease

NeuroOp Guru: What a big data study reveals about NAION and stroke risk

Port Delivery System Therapies in Retinal Vascular Diseases

Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study

Safety Considerations in Retinal Vascular Diseases